biotech

automatic inspection machine

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health ...
Read Full Story »
IPO

inVentiv Updates IPO Filing

inVentiv Group Holdings filed an amended Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were mentioned in this filing, ...
Read Full Story »
biotech word cloud

Why Regulus Is Tanking

Regulus Therapeutics Inc. (NASDAQ: RGLS) saw its shares cut in half early Tuesday morning following news of a clinical hold from the U.S. Food and Drug Administration (FDA). The company ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After ...
Read Full Story »
white pills

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked valuations ...
Read Full Story »
clinical trials

Why Nymox Pharmaceutical Took Off

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) shares made solid headway in Wednesday’s session on positive results from a cancer trial. The company announced results from its seven-year prospective placebo controlled double-blind ...
Read Full Story »
blood cells

Global Blood Therapeutics Rises After Pricing Secondary Offering

Global Blood Therapeutics Inc. (NASDAQ: GBT) shares saw a handy gain in the premarket on Tuesday, despite the company pricing its secondary offering below its previous price level. This could be the ...
Read Full Story »
forest fire

4 Red-Hot Biotech Stocks With Over 100% Upside Potential

Long-time aggressive investors know that biotechnology stocks can offer huge upside and also can get absolutely hammered, and in some cases go out of business. Needless to say, the biotech ...
Read Full Story »
graph

Gilead Sciences Bounces on Preliminary Results

Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of preliminary data from its HIV treatment. After the stock dropped ...
Read Full Story »
IPO

Selecta Biosciences Closes in on IPO

Selecta Biosciences has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) in regards to its initial public offering (IPO). The company intends to price its ...
Read Full Story »
Female patient on gurney

Could This Be a Turning Point for Fate Therapeutics?

Shares of Fate Therapeutics Inc. (NASDAQ: FATE) saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA) approval. Looking at the stock performance in 2016, ...
Read Full Story »
reprimand

6 Companies That Destroyed Shareholders Last Week

After the Federal Reserve announced that interest rates would not be raised on Wednesday, many would expect that the market would turn itself around after having about four down days in ...
Read Full Story »
IPO

Audentes Therapeutics Updates IPO Filing

Audentes Therapeutics filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in this filing, but ...
Read Full Story »
Pills and tablets

Paratek Makes Milestone Movement in Late-Stage Trial

Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) saw its shares take a solid jump early on Friday after the results from its late-stage trial were released. The company announced that the Phase ...
Read Full Story »
Medical interface

6 Biopharma Movers Making a Run on Wednesday

The broad markets appeared to be turning around in Wednesday’s session after posting losses in the past four sessions. One reason for this resurgence is a few biopharma companies making ...
Read Full Story »